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Aim: To investigate the effect of malignancy on the outcomes of patients with severe aortic 2 
stenosis (AS) and the management strategy for AS with malignancy.    3 
Methods: Using data of 3815 patients with severe AS in a retrospective multicenter registry 4 
(CURRENT AS registry), we compared 3-year clinical outcomes among three groups based 5 
on malignancy status: with malignancy currently under treatment including best supportive 6 
care (malignancy group), with a history of malignancy without any current treatment (past 7 
history group), or without history of malignancy (no malignancy group).  8 
Results: Patients in the malignancy group (N=124) were more often men and had higher 9 
prevalence of low body mass index, recurrence of malignancy, anemia, and asymptomatic 10 
status, despite comparable surgical risks and echocardiographic parameters. The malignancy 11 
group or the past history group (N=389) had significantly higher risk for all cause death (HR: 12 
2.49, 95%CI: 1.98-3.14; HR: 1.23, 95%CI: 1.04-1.46) and for malignancy-related death (HR: 13 
16.2, 95%CI: 10.64-24.54; HR: 3.66, 95%CI: 2.43-5.52) than the no malignancy group 14 
(N=3302). The excess risk for aortic valve-related death was not observed in the malignancy 15 
group (HR: 0.79, 95%CI: 0.48-1.29) and was lower in the past history group (HR: 0.72, 16 
95%CI: 0.53-0.96). In the malignancy group, the treatment strategy (surgery: N=16, 17 




Conclusions: Malignancy had marked effect on all-cause death and malignancy-related death 1 
in patients with severe AS. History of malignancy also had a smaller but significant effect on 2 
mortality. 3 
 4 
(Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic 5 









The prevalence of aortic stenosis (AS) and malignancy are both high in elderly people in 2 
developed countries. However, there is limited information on the influence of malignancy on 3 
outcomes of patients with severe AS; hence, there is no fixed treatment policy for patients with 4 
severe AS and malignancy. Thus, we investigated the effect of malignancy on the outcomes of 5 
patients with severe AS. We also investigated the management strategy for AS in patients with 6 
active malignancy.   7 
The main findings of this study are as follows: 1) Not only the malignant disease but also 8 
history of malignancy has a significant risk for all-cause death and malignancy-related death 9 
in patients with severe AS. 2) In patients with active malignancy and severe AS, the main 10 
reasons behind selecting aortic valve replacement/transcatheter aortic valve implantation 11 
(AVR/TAVI) strategy were the presence of symptoms related to AS, as well as requirement of 12 
AVR before non-cardiac surgery, and very severe AS. The common reasons for the choice of 13 
conservative treatment strategy were absence of symptoms, limited life expectancy due to 14 
diseases unrelated to AS, and refusal for AVR/TAVI. 3) The rates of perioperative 15 
complications and mortality for malignancy surgery were low both in patients before or 16 
without AVR/TAVI and in patients who underwent AVR/TAVI prior to malignancy surgery.  17 
When we consider the treatment choices, the malignancy status is very important for the 18 
prognosis in patients with severe AS.  19 
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Introduction  1 
With improvements in early detection and treatments for malignancy, patients with 2 
malignancy are living longer and more often with complete recovery from malignancy or 3 
with malignancy under control. As a result, malignancy is increasingly being recognized as a 4 
chronic disease. The growing cohort of survivors that exceeds 10 million was recently 5 
reported (1). The incidence of aortic stenosis (AS), which was accompanied with 6 
degenerative changes, is also increasing (2). The prevalence of severe AS may be up to 4.6% 7 
and 8.1% in people aged 75 or older and aged 85 or older, respectively(2-4). Thus, prolonged 8 
life expectancies of patients with malignant disease enabled simultaneous development of 9 
AS.  10 
However, information on the influence of malignancy on outcomes of patients with 11 
severe AS (5-8) is limited. There have been few opportunities to study this topic because of 12 
the exclusion criterion of randomized controlled trial and the benefit from therapy to AS 13 
being blunted by malignancy-related death. Recently, we reported an observational registry 14 
which enrolled all consecutive patients who met the criteria of severe AS in a multicenter 15 
fashion (9-11). The aim of the present study was to investigate the effect of active and 16 
inactive malignancies on the outcomes of severe AS. Furthermore, we examined the reasons 17 
of the management strategies in patients with AS and malignancy as well as the perioperative 18 





We enrolled 3815 patients with severe AS from 27 centers in Japan between January 3 
2003 and December 2011 in the CURRENT AS (Contemporary outcomes after sURgery and 4 
medical tREatmeNT in patients with severe Aortic Stenosis) registry (Supplementary 5 
Appendix) (9). Using the hospital database for transthoracic echocardiography, consecutive 6 
patients who met the definition of severe AS (peak aortic jet velocity [Vmax] > 4.0 m/s, mean 7 
aortic pressure gradient [PG] > 40 mm Hg, or aortic valve area [AVA] < 1.0 cm2) for the first 8 
time during the study period were enrolled in this registry (9). When stratified according to 9 
the initial treatment strategies after the index echocardiography, the entire cohort was divided 10 
into the conservative management cohort (N=2618) and initial AVR cohort (N=1197). The 11 
decision of the initial treatment strategy was based on the physicians’ discretion. Study design 12 
and patient enrollment in the registry have been previously described in detail (9).  13 
The study protocol was approved by the institutional review board of each 14 
participating center. The requirement of written informed consent was waived due to the 15 
retrospective nature of the study. Patient records were anonymized prior to analysis.  16 
 17 
Definitions of malignancy status and other conditions  18 
The study subjects were divided into three groups based on the malignancy status. 19 
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We defined the malignancy group as those with a malignancy currently under treatment, for 1 
which treatment is planned, or the best possible supportive care is being provided, whereas 2 
the past history group was defined as those with a history of malignancy but without the need 3 
for current treatment. No malignancy group was defined as those without a history of 4 
malignancy (Figure 1). Malignancy types were classified according to anatomic and system 5 
primary involvement (12). The date of first malignancy diagnosis was identified from the 6 
hospital record. Reasons for selecting each treatment strategy were placed into one of various 7 
categories in the malignancy group; however, detailed reasons allowed for overlaps. We 8 
defined anemia according to the World Health Organization criteria (hemoglobin < 13.0 g/dL 9 
in men and < 12.0 g/dL in women). Results of two-dimensional transthoracic 10 
echocardiography were analyzed at index echocardiography. The left ventricular ejection 11 
fraction (LVEF) was measured using the Teichholz method or the modified Simpson’s rule 12 
method.  13 
 14 
Outcome measures 15 
The primary outcome measure for the present analysis was all-cause death during the 16 
3-year follow-up period. The secondary outcome measures were malignancy-related death 17 
and aortic valve-related death. The cause of death was classified according to the Valve 18 
Academic Research Consortium definitions and adjudicated by a clinical event committee 19 
10 
 
(11, 13, 14). Malignancy-related death was defined as death where malignancy was the 1 
primary causes for the deteriorating general condition. Aortic valve-related death included 2 
aortic procedure-related death, sudden death, death caused by heart failure potentially related 3 
to the aortic valve, and death due to aortic valve endocarditis. Sudden death was defined as 4 
death within 24 hours after the manifestation of symptoms, death during sleep, or 5 
unwitnessed death in patients who had been stable until then. When obvious non-cardiogenic 6 
causes were identified, the deaths were excluded from the definition of sudden death. 7 
 8 
Statistical analysis 9 
In the present analysis, 1) we compared the baseline characteristics and 3-year 10 
clinical outcomes among the three groups on the basis of malignancy status in the entire 11 
cohort and each treatment strategy, 2) we investigated reasons behind selecting each 12 
treatment strategy for AS in the malignancy group, and 3) we compared perioperative 13 
complications of the surgery for malignancy between those patients with or without AVR 14 
before malignancy surgery.  15 
The categorical variables were expressed as numbers and percentages and were 16 
compared using a chi-square test or Fisher’s exact test. Continuous variables were expressed 17 
as mean ± standard deviation or median with interquartile range (IQR). Based on their 18 
distribution, continuous variables were compared using the Student’s t-test or the Wilcoxon 19 
11 
 
rank sum test between the two groups and the one-way analysis of variance or Kruskal-Wallis 1 
test across the three groups.  2 
To compare the 3-year clinical outcomes among the three groups in the entire cohort 3 
and each treatment strategy, the probability of all-cause death was estimated using the 4 
Kaplan-Meier method; the log-rank test was used for univariate comparisons. Cumulative 5 
incidence rates of malignancy-related or aortic valve-related death were estimated by using 6 
the Gray method (15), accounting for the competing risk of death other than malignancy-7 
related death or aortic valve-related death, respectively. To estimate the risk of the 8 
malignancy group and past history group relative to the no malignancy group during the 9 
entire follow-up period, a multivariable Cox proportional hazards model was developed for 10 
the all-cause death, and multivariable Cox proportional hazards models described by Fine and 11 
Gray subdistribution hazard model (16) were developed for the malignancy-related death and 12 
aortic valve-related death according for the competing risk of death other than malignancy-13 
related death or aortic valve-related death, respectively. The results were expressed as hazard 14 
ratios (HRs) and 95% confidence intervals (CIs). We selected 22 clinically relevant risk-15 
adjusting variables (Table 1) by using dummy variables, with the center incorporated as the 16 
stratification variable. This was consistent with our previous study (9), except for the addition 17 
of admission for heart failure as a risk-adjusting variable. The subgroup analyses for the 18 
primary and secondary outcome measures were also performed in the conservative 19 
12 
 
management cohort and the initial AVR cohort according to the intention-to-treat principle, 1 
regardless of the actual performance of AVR. 2 
All statistical analyses were conducted by a physician (E.M. or T.Kato) and a 3 
statistician (T.M.) using JMP 10.0.2 or SAS 9.4 (SAS Institute Inc., Cary, North Carolina). 4 
All the reported P values were two-tailed, and the level of statistical significance was set at P 5 




Baseline clinical and echocardiographic characteristics 2 
Among the 3815 patients, 124 patients had malignancy currently under treatment, 3 
for which treatment was planned, or the best supportive care was being provided (malignancy 4 
group), 389 had a past history of malignancy (past history group), and 3302 patients had no 5 
history of malignancy (no malignancy group) (Figure 1). Regarding the baseline 6 
characteristics, patients in the malignancy group were more often male and had a higher 7 
prevalence of low body mass index, recurrence of malignancy, diabetes on insulin therapy, 8 
anemia, chest wall irradiation, and liver cirrhosis, while they had lower prevalence of 9 
hypertension, aortic/peripheral vascular disease, and symptoms related to AS (Table 1). 10 
Surgical risk scores were comparable among the three groups. All echocardiographic 11 
parameters except the left ventricular posterior wall thickness were comparable across the 12 
three groups. Initial AVR strategy was least often taken in the malignancy group (Table 1).  13 
 14 
Clinical outcomes 15 
The median follow-up duration after the index echocardiography was 1176 (IQR: 16 
733-1618) days, with a 93% follow-up rate at 2 years. The cumulative 3-year incidence of 17 
AVR/TAVI was significantly lower in the malignancy group (24.4%) than in the past history 18 
group and no malignancy groups (past history group: 46.3%, no history group: 49.5%, 19 
14 
 
P<0.001) (Figure 2A). During the follow-up, 25 patients were undergoing AVR (n=24)/TAVI 1 
(n=1) in the malignancy group, 164 patients were undergoing AVR (n=159)/TAVI (n=5) in 2 
the past history group, and 1555 patients were undergoing AVR (n=1521)/TAVI (n=34) in the 3 
no history group. The proportion of patients undergoing TAVI to surgical AVR/TAVI was not 4 
different among the three groups (P=0.66). The cumulative 3-year incidence of the primary 5 
outcome measure (all-cause death) was markedly higher in the malignancy group and slightly 6 
but significantly higher in the past history group than in the no history group (64.9%, 39.0%, 7 
and 28.4%, P<0.001) (Figure 2B). The cumulative 3-year incidence of malignancy-related 8 
death was also markedly higher in the malignancy group than in the past history group and 9 
the no history group (36.4%, 8.6%, and 1.7%, P<0.001) (Figure 2C), while the cumulative 10 
incidence of aortic valve-related death did not differ significantly among the three groups 11 
(Figure 2D). After adjusting for confounders, the excess risk in the malignancy group and 12 
past history group relative to the no malignancy group for all-cause death remained 13 
significant (HR: 2.49, 95%CI: 1.98-3.14, P<0.001; HR: 1.23, 95%CI: 1.04-1.46, P=0.01, 14 
respectively, Supplementary Table 1). In malignancy-related death, the excess risks in the 15 
malignancy and past history groups relative to the no malignancy group were significant 16 
(HR: 16.2, 95% CI: 10.64-24.54, P<0.001 and HR: 3.66, 95% CI: 2.43-5.52, P<0.001, 17 
respectively) (Supplementary Table 1). For aortic valve-related death, the risk in the 18 
malignancy group was comparable to that in the no malignancy group (HR: 0.79, 95% CI: 19 
15 
 
0.48-1.29, P=0.35), while the risk of the past history group was lower than that in the no 1 
malignancy group (HR: 0.72, 95% CI: 0.53-0.96, P=0.03) (Supplementary Table 1). 2 
 3 
Subgroup analysis according to the treatment strategy 4 
In the conservative management cohort (N=2618, Supplementary Table 2), the 5 
results of cumulative 3-year incidence of the primary and secondary outcome measures 6 
among the three groups and the excess risk of the malignancy group were consistent with 7 
those in the entire cohort (Supplementary Figure 1A, 1B, 1C, and 1D, and Supplementary 8 
Table 3). In the initial AVR cohort (N=1197, Supplementary Table 4), the cumulative 9 
incidence of surgical AVR or TAVI did not differ among the three groups categorized by 10 
malignancy status (Supplementary Figure 2A). No patient had aortic valve-related death in 11 
the malignancy group (Supplementary Figure 2B, 2C and 2D, and Supplementary Table 5). 12 
The proportion of patients undergoing TAVI to surgical AVR/ TAVI did not differ among the 13 
three groups in the conservative management and initial AVR cohorts. (P=0.51, P=0.20, 14 
respectively) (Supplementary Table 6) 15 
 16 
Reasons for selecting treatment strategies in the malignancy group 17 
In the malignancy group, AVR was selected as the first-line treatment in 16 out of 18 
124 patients (12.9%). In the past history group, AVR was selected for 114 out of 389 patients 19 
16 
 
(29.3%), while 1067 out of 3302 patients (32.3%) in the no malignancy group received AVR 1 
as the first-line treatment (Figure 1). In the malignancy group, the most common types of 2 
malignancies were prostate cancer (N=24; 19.4%), lung cancer (N=19; 15.3%), gastric cancer 3 
(N=13; 10.5%), hepatic cancer (N=8; 6.5%), and breast cancer (N=8; 6.5%) (Supplementary 4 
Table 7). The presence of metastasis was recognized in 38 patients. Seventy-eight patients 5 
were recognized as not having metastasis, and six patients were of unknown status. The 6 
cumulative incidence of AVR/TAVI was not statistically significant between the groups with 7 
and without metastasis (Supplementary Figure 3A), but the incidence of the overall mortality 8 
and malignancy-related death was higher in the group with metastasis (Supplementary Figure 9 
3B, and 3C). Table 2 summarizes the reasons behind selecting conservative management or 10 
AVR/TAVI in the malignancy group. In the conservative management cohort, absence of 11 
symptoms was the most common reason, limited life expectancy due to diseases unrelated to 12 
AS was the second, and age was the third common reason behind selecting conservative 13 
management. Six patients declined the AVR/TAVI. In the AVR cohort, the reasons were 14 
symptomatic, as well as requirement of AVR before non-cardiac surgery, and very severe AS.  15 
 16 
Perioperative complications of surgery for malignancy 17 
Surgery for malignancy was performed in 35 patients with malignancy. We presented 18 
the characteristics and perioperative complications in patients undergoing surgery for 19 
17 
 
malignancy in Table 3. Surgery was performed on 30 patients for malignancy before or 1 
without AVR/TAVI and five patients after AVR/TAVI. Three patients (43%) who underwent 2 
surgery for malignancy after AVR/TAVI had very severe AS, while only one patient (3%) 3 
with surgery for malignancy before or without AVR/TAVI had very severe AS. STS scores 4 
were comparable. There were no procedure complications within 30 days in both groups. One 5 
patient died within 30 days of the surgery for malignancy before or without AVR/TAVI group, 6 




The main findings of this study are as follows: 1) Malignancy had a marked effect 2 
on all-cause mortality and malignancy-related mortality and was associated with a lower rate 3 
of AVR/TAVI. 2) Past history of malignancy had a smaller but significant effect on these 4 
mortalities but no substantial effect on the rate of AVR/TAVI. 3) In patients with malignancy, 5 
the main reasons behind selecting AVR/TAVI strategy were HF symptoms and severity of AS, 6 
whereas the common reasons for the choice of conservative treatment strategy were high 7 
operative risk and limited life expectancy. 4) The rates of perioperative complications and 8 
mortality for malignancy surgery were low both in patients before or without AVR/TAVI and 9 
in patients who had underwent AVR/TAVI prior to malignancy surgery.  10 
 11 
Multiple models have been developed to predict accurately operative and early 12 
mortality following aortic valve(17) and heart surgery(18-21), but none of these models has 13 
considered the additional complexity related to a malignancy diagnosis. Moreover, no 14 
differences in STS scores were found among the three groups classified according to the 15 
presence of malignancy. Patients with AS and malignancy were less likely to have symptoms 16 
of AS. One reason for this might be that the malignancy status may mask the symptoms of AS 17 
through decreased physical activity, which is common in patients with malignancy. Another 18 
reason might be related to the screening of cardiovascular disease in patients with 19 
19 
 
malignancy, leading to diagnosis of severe AS without symptoms. Despite the lack of 1 
malignancy in the operative risk models, our data may support that clinically relevant choices 2 
had been made for the surgical AVR or conservative management in patients with 3 
malignancy, considering the relatively low rate of malignancy-related mortality in the AVR 4 
cohort. Another consideration is that terminally ill patients may not have undergone 5 
echocardiography initially and may not have been identified to be included in this study. 6 
There might be patients with malignancy and severe AS who had not undergone 7 
echocardiography as it had not been recognized by their oncologists or who felt that further 8 
investigation was not required due to the prognosis from their malignant disease, as this was 9 
an observational study based on the hospital database for transthoracic echocardiography.  10 
The malignancy group also showed high mortality due to malignancy. In clinical 11 
practice, the presence of malignancy in patients with severe AS is often considered a 12 
contraindication to surgical aortic valve replacement (22). The recent progress in TAVI has 13 
allowed extending the overall life expectancy of patients with malignancy to more than 1 year 14 
(7). However, it is difficult to determine the length of life expectancy permitting TAVI. We 15 
also considered decreased daily life activities, which are due to malignancy or AS, as well as 16 
other surgical risk when accounting for TAVI indication. The past history of malignancy had 17 
a small but a significant effect on mortality. It was mainly due to the increase of malignancy-18 
related death. Various studies reported that anti-cancer drug had cardiotoxicity and increase 19 
20 
 
the risk of heart failure (23, 24). In our study, there were no differences in cardiac function or 1 
pressure gradient among the three groups. Based on the competing risk model, the risk of 2 
aortic valve-related death was lower in the past history group. Close attention to the potential 3 
recurrence of malignancy or newly developed malignancy might decrease aortic valve-related 4 
death through frequent contact with health care providers in the past history group.  5 
There is a paucity of data on the safety of the surgery for malignancy in the presence 6 
of severe AS. Malignant disease might cause serious perioperative complications such as 7 
bleeding (25) due to vulnerable tissue and infection (26) due to cachexia if AVR was 8 
performed in the presence of malignancy. In addition, invasive AVR might cause the delay of 9 
the treatment of malignancy. In this study, we evaluated the perioperative complications in 10 
patients who underwent malignancy surgery in the presence of severe AS (“malignancy first” 11 
strategy) and in those who underwent malignancy surgery after AVR (“AVR first” strategy) in 12 
the registry data. We could not draw solid conclusions due to the small number of patients, 13 
although there were no significant differences in the rate of perioperative complications. A 14 
prospective study by Watanabe et al. (7) in Japan reported that patients with malignancy with 15 
severe AS who underwent TAVI had similar 1-year mortality as patients without malignancy. 16 
By contrast, another prospective study by Mangner et al. (27) reported that malignancy in 17 
patients undergoing TAVI more adversely affected 1-year mortality compared with that in 18 
those with a history of malignancy and controls without known malignant disease. This 19 
21 
 
discrepancy might be due to variances in malignancy type distribution and racial disparities 1 
(28). Further studies, which are retrospective or prospective, are needed to answer questions 2 
about what malignancy type, malignancy stage, and level of surgical invasiveness would 3 
allow each strategy.  4 
The process of decision-making for the treatment strategy is complicated in patients 5 
whom malignant disease and cardiac disease coexist because the prognosis and 6 
cardiovascular complications of malignancy therapy vary depending on the malignancy type, 7 
stage, and therapy. As some patients with long-term thoracic radiation therapy have radiation-8 
related pericardial fibrosis (29), TAVI might be an indication for such patients (30, 31). It is 9 
necessary to decide treatment strategy considering various factors based on perspectives from 10 
cardiovascular physicians, cardiac surgeons, oncologist, and radiologist. There is a report that 11 
incidental findings of tumor in a computer tomography before undergoing TAVI did not have 12 
a significant effect on the outcomes for elderly patients with severe AS based on the decision 13 
of the interdisciplinary heart team (6). A heart team approach with oncologists and radiologist 14 
can make clinically relevant decision-making easier and reduce the perioperative 15 
complications. Thus, it is important to investigate contemporary data when we consider the 16 
choice of “TAVI first” strategy, “surgical AVR first” strategy, or “malignancy first” strategy in 17 





First, the precise staging and lines of prior chemotherapy were not collected; 2 
therefore, we could not analyze the data according to malignancy staging or therapy. Second, 3 
the exact expected life expectancy of each patient in the malignancy group was unclear. 4 
However, a substantial portion of patients was estimated to have a limited life expectancy in 5 
the malignancy group. Third, categorization of the circumstances surrounding each death, 6 
particularly the mechanism of death, was related to the process of adjudication and may be 7 
incomplete. It is unclear whether sudden death or endocarditis is due to pulmonary embolism 8 
or endocarditis related malignancy. Fourth, we did not collect the data about a heart team 9 
approach nor the referral for oncologists. Fifth, there remain unmeasured confounders 10 
affecting the mortality, although we conducted extensive statistical adjustment for the 11 
measured confounders. Sixth, the number of patients in the malignancy group according to 12 
the initial treatment strategy and number of patients who underwent surgery for the active 13 
malignancy with severe AS were very small. However, in conjunction with other reports, our 14 
data shed light on the practice for the complicated conditions of patients with malignancy and 15 
severe AS. Seventh, the number of patients undergoing TAVI in our study was too small to 16 
analyze the difference between patients undergoing TAVI and AVR. Finally, although this 17 
study was based on a registry in Japan, the prevalence of malignancy might be different 18 
depending on the countries and race. The external validity should be confirmed to further 19 
23 
 
investigate this issue, and a study in another country or race is required.  1 
 2 
Conclusion 3 
Active malignancy had a marked effect on all-cause death and malignancy-related 4 
death in patients with severe AS. History of malignancy also had a smaller but significant 5 
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Figure 1. Study patient flow.  
AVR=aortic valve replacement 
 
Figure 2. Kaplan-Meier curves for the cumulative 3-year incidence of clinical events 
(A) surgical AVR or TAVI during follow-up, (B) the primary outcome measure (all-cause 
death), (C) malignancy-related death, and (D) aortic valve-related death.  
AVR=aortic valve replacement, and TAVI=transcatheter aortic valve implantation. 
Table 1. Baseline clinical and echocardiographic characteristics in the malignancy group, 












Clinical characteristics     
Age, years* 78.8±7.1 78.7±8.3 77.6±10.0 0.045 
Age ≥80 years 53 (43) 196 (50) 1480 (45) 0.14 
Male* 65 (52) 191 (49) 1187 (36) <0.001 
BMI  21.1±3.5 21.7±3.7 21.8±3.9 0.16 
BMI <22 * || 88 (71) 222 (57) 2016 (61) 0.02 
BSA, m2  1.45±0.18 1.48±0.18 1.46±0.19 0.14 
Initial AVR group 16 (13) 114 (29) 1067 (32) <0.001 
Recurrence of malignancy 45 (36) 11 (3) 0 <0.001 
Hypertension* 75 (60) 265 (68) 2327 (70) 0.042 
Current smoking* 6 (5) 17 (4) 173 (5) 0.75 
History of smoking 34 (27) 108 (28) 688 (21) 0.002 
Diabetes mellitus 35 (28) 92 (24) 770 (23) 0.45 
  On insulin therapy* 13 (10) 20 (5) 155 (5) 0.01 
Tables
Coronary artery disease*  40 (32) 123 (32) 981 (30) 0.63 
Prior myocardial infarction* 10 (8) 36 (9) 277 (8) 0.83 
Prior symptomatic stroke* 22 (17) 50 (13) 431 (13) 0.31 
Atrial fibrillation or flutter* 17 (14) 83 (21) 728 (22) 0.09 
Aortic/peripheral vascular 
disease* 
2 (2) 36 (9) 244 (7) 0.02 
Serum creatinine, mg/dL* 0.9 (0.7-1.3) 0.9 (0.7-1.4) 0.9 (0.7-1.2) 0.25 
Dialysis* 12 (10) 47 (12) 346 (10) 0.59 
Anemia* § 93 (75) 234 (60) 1790 (54) <0.001 
Chest wall irradiation 10 (8) 10 (3) 5 (0.2) <0.001 
Immunosuppressive therapy 7 (6) 11 (3) 113 (3) 0.32 
Chronic lung disease ≥moderate* 4 (3) 14 (4) 94 (3) 0.69 
Liver cirrhosis* 7 (6) 12 (3) 19 (1) <0.001 
STS score (PROM), % 3.6 (2.3-5.9) 4.0 (2.5-7.0) 3.8 (2.2-6.6) 0.17 
Symptoms at index 
echocardiography 
44 (35) 194 (50) 1767 (54) <0.001 
Chest pain 14 (11) 46 (12) 438 (13) 0.35 
Syncope 3 (2) 26 (7) 169 (5) 0.12 
Chronic exertional dyspnea 33 (27) 148 (38) 1422 (43) <0.001 
Admission for heart failure at 
index echocardiography* 
18 (15) 75 (19) 697 (21) 0.16 
Echocardiographic variables     
Vmax, m/s 4.0±0.9 4.1±0.8 4.1±0.9 0.16 
  Vmax >4m/s* 67 (54) 224 (56) 1894 (57) 0.76 
Peak aortic PG, mmHg 68±30 70±28 72±32 0.11 
Mean aortic PG, mmHg 39±18 39±17 41±20 0.08 
AVA (equation of continuity), cm2 0.75±0.16 0.72±0.18 0.72±0.19 0.21 
LV end-diastolic diameter, mm 45±6 46±7 46±7 0.61 
LV end-systolic diameter, mm 30±7 31±8 30±8 0.56 
LVEF, %  64.0±11.7 62.3±13.8 63±13.5 0.47 
  LVEF <68%* 72 (58) 231 (59) 1939 (59) 0.96 
 IVST (mm) 11±2 11±2 11±2 0.40 
 LVPW (mm) 10±2 11±2 11±2 0.02 
Any combined valvular disease 
(moderate or severe)* 
50 (40) 160 (41) 1348 (41) 0.99 
TR pressure gradient ≥40 mmHg* 21 (17) 60 (15) 525 (16) 0.92 
Values are number (%), mean ± SD, or median (interquartile range). 
P values were calculated from a chi-square test or Fisher’s exact test for categorical variables, and the one-way 
analysis of variance or Kruskal-Wallis test for continuous variables. 
|| Body mass index was calculated as weight in kilograms divided by height in meters squared. 
§ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dL in women and <13.0 
g/dL in men).  
* Potential risk-adjusting variables selected for Cox proportional hazard models. 
AS=aortic stenosis, AVA=aortic valve area, AVR=aortic valve replacement, BMI=body mass index, BSA=body 
surface area, Cre=creatinine, LV=left ventricular, LVEF=left ventricular ejection fraction, LVPW= left ventricular 
posterior wall, IVST= interventricular septum thickness, PG=pressure gradient, PROM=predicted risk of 
mortality, SD=standard deviation, STS=Society of Thoracic Surgeons, TR=tricuspid regurgitation, and 
Vmax=peak aortic jet velocity  
Table 2. Reason why treatment strategy was chosen for AS in the malignancy group 
Reasons N of patients (N=124) Detailed reasons*  N 
Conservative management cohort (N=108)   
No indication for AVR 51 Asymptomatic 46 
Improved symptoms by medical treatment 3 
Symptoms by coronary artery disease 2 
High risk for AVR/TAVI 51 Limited life expectancy due to diseases unrelated to AS  36 
Aged 15 
Liver cirrhosis 5 
Renal failure 5 
Cognitive dysfunction 4 
Prior open surgery 2 
Low respiratory function 2 
Very high-risk operative procedure 1 
Malnutrition 1 
Patients refusal of AVR/TAVI 6   
Initial AVR cohort (N=16)   
Symptomatic AS 11 Heart failure 8 
 Chest pain 4 
 Syncope 1 
Asymptomatic AS 5 AVR was required before non-cardiac surgery 3 
 Very severe AS 3 
*Detailed reasons allowed for overlaps. 
TAVI=transcatheter aortic valve implantation 
Other abbreviations are same as in Table 1.  
Table 3. Characteristics and perioperative complications in patients undergoing surgery 
for malignancy  
 Surgery for malignancy 
without AVR or before AVR 
group (N=30) 




Age (years) 77.1±6.9 71.7±5.5 0.07 
LVEF<50% 1 (3) 0 (0) 0.62 
Vmax>5m/s 1 (3) 3 (43) 0.002 
Symptom at index 
echocardiography 
6 (20) 2 (29) 0.62 
Admission for heart failure at 
Index UCG 
3 (10) 2 (29) 0.20 
STS (PROM) score, %  2.7 (2.1-3.8) 3.9 (1.7-3.9) 0.59 
Involved organs Lung, Stomach, Breast, Gall 
bladder, Prostate 
Stomach, Esophagus, Kidney 
and urethra, Larynx 
 
Anesthesia procedures    
General anesthesia 25 (80%) 4 (80%) 0.85 
Lumbar anesthesia 4 0  
Intravenous anesthesia 1 1  
Procedure complication 
(within 30 days) 
   
Worsening heart failure 0 0  
Stroke 0 0  
Death (within 30 days) 1 0 0.68 
Death due to malignancy  1 0  
Values are number (%), mean ± SD, or median (interquartile range). 
Abbreviations are same as in Table 1. 
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Figure 2(A)  
  
 
Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  19 21 22 
N of patients at risk 124 60 38 21 
Cumulative incidence  17.9% 21.3% 24.4% 
Past history 
group 
N of patients with at least 1 event  123 140 152 
N of patients at risk 389 197 144 94 




N of patients with at least 1 event  1178 1324 1431 
N of patients at risk 3302 1625 1241 826 
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Log rank P<0.001 
Past history group 





Figure 2(B)   
 
 
Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  45 66 77 
N of patients at risk 124 75 52 32 
Cumulative incidence  37.1% 54.9% 64.9% 
Past history 
group 
N of patients with at least 1 event  74 114 146 
N of patients at risk 389 307 262 189 




N of patients with at least 1 event  465 701 874 
N of patients at risk 3302 2672 2345 1747 
































Log rank test: P<0.001 
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Figure 2(C)  
 
 
Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  25 36 43 
N of patients at risk 124 75 52 32 
Cumulative incidence  20.7% 30.0% 36.4% 
Past history 
group 
N of patients with at least 1 event  14 23 32 
N of patients at risk 389 307 262 189 




N of patients with at least 1 event  14 34 51 
N of patients at risk 3302 2672 2345 1747 






































Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  10 14 15 
N of patients at risk 124 75 52 32 
Cumulative incidence  8.2% 11.6% 12.5% 
Past history 
group 
N of patients with at least 1 event  23 34 42 
N of patients at risk 389 307 262 189 




N of patients with at least 1 event  245 345 408 
N of patients at risk 3302 2672 2345 1747 
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Supplementary figure legend 
Supplementary Figure 1. Kaplan-Meier curves for the cumulative 3-year incidence of 
clinical events in the conservative management cohort  
(A) surgical AVR or TAVI during follow-up, (B) the primary outcome measure (all-cause 
death), (C) malignancy-related death, (D) aortic valve-related death. 
AVR=aortic valve replacement, and TAVI=transcatheter aortic valve implantation. 
 
Supplementary Figure 2. Kaplan-Meier curves for the cumulative 3-year incidence of 
clinical events in the initial AVR cohort 
(A) surgical AVR or TAVI during follow-up, (B) the primary outcome measure (all-cause 
death), (C) malignancy-related death, (D) aortic valve-related death. 
AVR=aortic valve replacement, and TAVI=transcatheter aortic valve implantation. 
 
Supplementary Figure 3. Kaplan-Meier curves for the cumulative incidence of clinical 
events according to the malignancy status in the malignancy group; metastatic versus non 
metastatic 
(A) surgical AVR or TAVI during follow-up, (B) the primary outcome measure (all-cause 
death), (C) malignancy-related death 
AVR=aortic valve replacement, and TAVI=transcatheter aortic valve implantation.  
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Supplementary Figure 1 (A)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  4 6 7 
N of patients at risk 108 60 37 21 
Cumulative incidence  5.6% 9.8% 13.0% 
Past history 
group 
N of patients with at least 1 event  11 27 39 
N of patients at risk 275 195 143 94 




N of patients with at least 1 event  133 278 385 
N of patients at risk 2235 1620 1238 823 
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Log rank P=0.25 
Past history group 




Supplementary Figure 1 (B)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  42 61 71 
N of patients at risk 108 64 43 24 
Cumulative incidence  39.5% 57.7% 68.1% 
Past history 
group 
N of patients with at least 1 event  63 97 123 
N of patients at risk 275 205 167 120 




N of patients with at least 1 event  383 583 734 
N of patients at risk 2235 1740 1481 1106 

































Log rank test: P<0.001 
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Supplementary Figure 1 (C)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  24 34 41 
N of patients at risk 108 64 43 24 
Cumulative incidence  22.6% 32.2% 39.5% 
Past history 
group 
N of patients with at least 1 event  13 22 30 
N of patients at risk 275 205 167 120 




N of patients with at least 1 event  12 27 37 
N of patients at risk 2235 1740 1481 1106 
































Gray’s test: P<0.001 
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Supplementary Figure 1(D)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  10 14 15 
N of patients at risk 108 64 43 24 
Cumulative incidence  9.4% 13.2% 14.3% 
Past history 
group 
N of patients with at least 1 event  18 29 35 
N of patients at risk 275 205 167 120 




N of patients with at least 1 event  192 287 350 
N of patients at risk 2235 1740 1481 1106 

































Gray’s test: P=0.13 
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Supplementary Figure 2 (A) 
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  15 15 15 
N of patients at risk 16 0 0 0 
Cumulative incidence  93.8% 93.8% 93.8% 
Past history 
group 
N of patients with at least 1 event  112 113 113 
N of patients at risk 114 2 1 0 




N of patients with at least 1 event  1045 1046 1046 
N of patients at risk 1067 5 3 3 
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Log rank P=0.08 
Past history group 




Supplementary Figure 2 (B)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  3 5 6 
N of patients at risk 16 11 9 8 
Cumulative incidence  20.6% 35.0% 42.2% 
Past history 
group 
N of patients with at least 1 event  11 17 23 
N of patients at risk 114 101 95 69 




N of patients with at least 1 event  82 118 140 
N of patients at risk 1067 932 864 641 

































Log rank test: P<0.001 
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Supplementary Figure 2 (C)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  1 2 2 
N of patients at risk 16 11 9 8 
Cumulative incidence  7.2% 14.4% 14.4% 
Past history 
group 
N of patients with at least 1 event  1 1 2 
N of patients at risk 114 102 95 69 




N of patients with at least 1 event  2 7 14 
N of patients at risk 1067 932 864 641 
































Gray’s test: P=0.01 
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Supplementary Figure 2 (D)  
 
 Interval (years) 0 1 2 3 
Malignancy 
group 
N of patients with at least 1 event  0 0 0 
N of patients at risk 16 11 9 8 
Cumulative incidence  0% 0% 0% 
Past history 
group 
N of patients with at least 1 event  5 5 7 
N of patients at risk 114 102 95 69 




N of patients with at least 1 event  53 58 58 
N of patients at risk 1067 932 864 644 
































Gray’s test: P=0.61 
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Supplementary Figure 3 (A)  
 
 Interval (years) 0 1 2 3 
Metastatic 
N of patients with at least 1 event  3 3 3 
N of patients at risk 38 17 10 5 
Cumulative incidence  10.1% 10.1% 10.1% 
Non 
metastatic 
N of patients with at least 1 event  15 17 18 
N of patients at risk 78 39 25 14 
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Supplementary Figure 3 (B)  
 
 Interval (years) 0 1 2 3 
Metastatic 
N of patients with at least 1 event  18 24 28 
N of patients at risk 38 18 11 5 
Cumulative incidence  49.0% 66.8% 78.9% 
Non 
metastatic 
N of patients with at least 1 event  24 38 44 
N of patients at risk 78 52 37 24 
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Supplementary Figure 3 (C)  
 
 Interval (years) 0 1 2 3 
Metastatic 
N of patients with at least 1 event  13 17 21 
N of patients at risk 38 18 11 5 
Cumulative incidence  38.8% 54.7% 71.2% 
Non 
metastatic 
N of patients with at least 1 event  11 18 21 
N of patients at risk 78 52 38 24 
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Supplementary Table 1. Clinical outcomes according to the malignancy status 
Supplementary Table 2. Baseline clinical and echocardiographic characteristics in the 
malignancy group, past history group, and no malignancy group in the conservative 
management cohort 
Supplementary Table 3. Clinical outcomes according to the malignancy status in the 
conservative management cohort 
Supplementary Table 4. Baseline clinical and echocardiographic characteristics in the 
malignancy group, past history group, and no history group in the Initial AVR cohort 
Supplementary Table 5. Clinical outcomes according to the malignancy status in the AVR 
cohort 
Supplementary Table 6. The number of patients who underwent TAVI according to the 
malignancy status in the conservative management and initial AVR cohorts 
Supplementary Table 7. Types of malignancy in the malignancy group (N=124)  
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Supplementary Table 1. Clinical outcomes according to the malignancy status 
 
N of patients with event/N of 
patients at risk 
(Cumulative 3-year incidence)  
P value 
Adjusted risk 
HR 95% CI P value 
All-cause death 
No malignancy group 1189/3302 (28.4%)  
<0.001 
1 (reference)   
Past history group 173/389 (39.0%) 1.23 1.04-1.46 0.01 
Malignancy group 87/124 (64.9%) 2.49 1.98-3.14 <0.001 
Malignancy 
related death 
No malignancy group 80/3302 (1.7%) 
<0.001 
1 (reference)   
Past history group 35/389 (8.6%) 3.66 2.43-5.52 <0.001 
Malignancy group 46/124 (36.4%) 16.2 10.64-24.54 <0.001 
Aortic valve 
related death 
No malignancy group 538/3302 (13.1%)  
0.35 
1 (reference)   
Past history group 53/389 (11.2%) 0.72 0.53-0.96 0.03 
17 
 
Malignancy group 18/124 (12.5%) 0.79 0.48-1.29 0.35 
CI=confidence interval, HR=hazard ratio  
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Supplementary Table 2. Baseline clinical and echocardiographic characteristics in the 
malignancy group, past history group, and no malignancy group in the conservative 
management cohort 
Variable 












Age, years 79.6±6.8 80.0±8.4 79.7±9.7 0.91 
Age ≥80 years 50 (46) 158 (57) 1222 (55) 0.14 
Male 56 (52) 135 (49) 745 (33) <0.001 
BMI <22 || 78 (72) 169 (61) 1457 (65) 0.13 
BSA, m2  1.44±0.18 1.46±0.19 1.43±0.18 0.03 
Recurrence of malignancy 44 (41) 10 (4) 0 <0.001 
Hypertension 65 (60) 188 (68) 1607 (72) 0.02 
Current smoking 5 (5) 14 (5) 94 (4) 0.78 
History of smoking 29 (27) 71 (26) 416 (19) 0.003 
Diabetes mellitus 31 (29) 64 (23) 526 (24) 0.46 
  On insulin therapy 11 (10) 12 (4) 107 (5) 0.04 
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Coronary artery disease 34 (31) 78 (28) 634 (28) 0.78 
Prior symptomatic stroke 21 (19) 35 (13) 340 (15) 0.24 
Atrial fibrillation or flutter 15 (14) 61 (22) 545 (24) 0.04 
Serum creatinine, mg/dL 0.9 (0.7-1.1) 1.0 (0.7-1.6) 0.9 (0.7-1.3) 0.17 
Cre>2mg/dl and Hemodialysis 14 (13) 52 (19) 340 (15) 0.21 
Anemia§ 82 (76) 172 (63) 1234 (55) <0.001 
Chest wall irradiation 8 (7) 7 (3) 3 (0.1) <0.001 
Immunosuppressive therapy 7 (6) 10 (4) 83 (4) 0.34 
Chronic lung disease (moderate or 
severe) 
3 (3) 11 (4) 79 (4) 0.84 
STS score (PROM), % 3.8 (2.4-5.9) 4.2 (2.8-7.8) 4.3 (2.6-7.5) 0.16 
Symptoms at index 
echocardiography 
32 (30 ) 110 (40) 958 (43) 0.003 
Chest pain 10 (9) 19 (7) 178 (8) 0.06 
Syncope 2 (2) 11 (4) 75 (3) 0.047 
Chronic exertional dyspnea 24 (22) 93 (34) 827 (37) <0.001 
Admission for heart failure at 
index echocardiography 




Vmax, m/s 3.9 (0.8) 3.9 (0.8) 3.9 (0.8) 0.99 
  Vmax >4m/s 52 (48) 129 (47) 1010 (45) 0.74 
Peak aortic PG, mmHg 63 (27) 62 (25) 63 (28) 0.94 
Mean aortic PG, mmHg 35 (15) 34 (16) 35 (17) 0.62 
AVA (equation of continuity),cm2 0.76 (0.16) 0.76 (0.17) 0.75 (0.18) 0.68 
LV end-diastolic diameter, mm 45 (6) 46 (7) 45 (7) 0.04 
LV end-systolic diameter, mm 29 (7) 31 (8) 30 (8) 0.10 
LVEF, %  64.1±11.9 62.0±14.3 62.8±13.2 0.34 
  LVEF <68% 63 (58) 161 (59) 1350 (60) 0.78 
 IVST (mm) 11 (2) 11 (2) 11 (2) 0.50 
 LVPW (mm) 10 (2) 11 (2) 11 (2) 0.10 
Any combined valvular disease 
(moderate or severe) 
41 (38) 116 (42) 922 (41) 0.75 
TR pressure gradient ≥40 mmHg 15 (14) 44 (16) 367 (16) 0.78 
Values are number (%), mean ± SD, or median (interquartile range). 
P values were calculated from a chi-square test or Fisher’s exact test for categorical variables, and the one-way 
analysis of variance or Kruskal-Wallis test for continuous variables. 
|| Body mass index was calculated as weight in kilograms divided by height in meters squared. 
§ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dL in women and <13.0 
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g/dL in men).  
AS=aortic stenosis, AVA=aortic valve area, BMI=body mass index, BSA=body surface area, Cre=creatinine, 
LV=left ventricular, LVEF=left ventricular ejection fraction, PG=pressure gradient, PROM=predicted risk of 
mortality, SD=standard deviation, STS=Society of Thoracic Surgeons, TR=tricuspid regurgitation, and 
Vmax=peak aortic jet velocity  
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Supplementary Table 3. Clinical outcomes according to the malignancy status in the conservative management cohort 
 
N of patients with event/N of patients at risk 
(Cumulative 5-year incidence [%])  
P value 
Adjusted risk 
HR 95% CI P value 
All-cause death 
No malignancy group 991/2235 (49.9%) 
<0.001 
1 (reference)   
Past history group 142/275 (55.9%) 1.25 1.04-1.51 0.02 
Malignancy group 28/108 (82.3%) 2.55 2.00-3.25 <0.001 
Malignancy 
related death 
No malignancy group 58/2235 (3.0%) 
<0.001 
1 (reference)   
Past history group 33/275 (13.1%) 5.04 3.22-7.89 <0.001 
Malignancy group 44/108 (43.7%) 19.06 12.24-29.68 <0.001 
Aortic valve 
related death 
No malignancy group 477/2235 (24.2%) 
0.13 
1 (reference)   
Past history group 46/275 (18.8%) 0.69 0.51-0.95 0.02 
Malignancy group 18/108 (18.0%) 0.83 0.49-1.38 0.47 
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CI=confidence interval, HR=hazard ratio 
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Supplementary Table 4. Baseline clinical and echocardiographic characteristics in the 
malignancy group, past history group, and no history group in the Initial AVR cohort 
Variable 












Age, years 73.7±6.7 75.7±7.2 73.1±9.1 0.01 
Age ≥80 years 3 (19) 38 (33) 258 (24) 0.08 
Male 9 (56) 56 (49) 442 (41) 0.15 
BMI <22 || 10 (63) 53 (46) 559 (52) 0.34 
BSA, m2  1.53±0.17 1.50±0.17 1.50±0.18 0.83 
Recurrence of malignancy 1 (6) 1 (1) 0 <0.001 
Hypertension 10 (63) 77 (68) 720 (67) 0.91 
Current smoking 1 (6) 3 (3) 79 (7) 0.16 
History of smoking 5 (31) 37 (32) 272 (25) 0.25 
Diabetes mellitus 4 (25) 28 (25) 244 (23) 0.90 
  On insulin therapy 2 (13) 8 (7) 48 (5) 0.18 
Coronary artery disease 6 (38) 45 (39) 347 (33) 0.31 
25 
 
Prior symptomatic stroke 1 (6) 15 (13) 91 (9) 0.24 
Atrial fibrillation or flutter 2 (13) 22 (19) 183 (17) 0.74 
Serum creatinine, mg/dL 0.9 (0.6-17) 0.8 (0.7-1.1) 0.8 (0.7-1.1) 0.97 
Cre>2mg/dl and Hemodialysis 2 (13) 15 (13) 135 (13) 0.99 
Anemia§ 11 (69) 62 (54) 556 (52) 0.38 
Chest wall irradiation 2 (13) 3 (3) 2 (0.2) <0.001 
Immunosuppressive therapy 0 1 (1) 30 (3) 0.38 
Chronic lung disease (moderate or 
severe) 
1 (6) 3 (3) 15 (1) 0.20 
STS score (PROM), % 2.9 (1.9-5.7) 3.0 (1.9-5.3) 2.7 (1.7-4.7) 0.32 
Symptoms at index 
echocardiography 
12 (75) 84 (74) 809 (76) 0.98 
Chest pain 4 (25) 27 (24) 260 (24) 0.10 
Syncope 1 (6) 15 (13) 94 (9) 0.62 
Chronic exertional dyspnea 9 (56) 55 (48) 595 (56) 0.64 
Admission for heart failure at 
index echocardiography 
7 (44) 23 (20) 240 (22) 0.11 
Echocardiographic variables 
Vmax, m/s 4.9 (0.8) 4.6 (0.7) 4.7 (0.8) 0.23 
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  Vmax >4m/s 15 (94) 95 (83) 884 (83) 0.52 
Peak aortic PG, mmHg 100 (31) 87 (26) 91 (32) 0.19 
Mean aortic PG, mmHg 60 (21) 51 (16) 54 (20) 0.18 
AVA (equation of continuity),cm2 0.64 (0.13) 0.64 (0.16) 0.65 (0.18) 0.79 
LV end-diastolic diameter, mm 50 (5) 46 (6) 47 (7) 0.03 
LV end-systolic diameter, mm 33 (6) 30 (6) 31 (9) 0.30 
LVEF, %  63.3±10.9 63.1±12.8 62.7±14.2 0.95 
  LVEF <68% 9 (56) 70 (61) 589 (55) 0.45 
 IVST (mm) 12 (2) 12 (2) 12 (2) 0.76 
 LVPW (mm) 12 (2) 12 (2) 12 (2) 0.93 
Any combined valvular disease 
(moderate or severe) 
9 (56) 44 (39) 426 (40) 0.40 
TR pressure gradient ≥40 mmHg 6 (38) 16 (14) 158 (15) 0.04 
Values are number (%), mean ± SD, or median (interquartile range). 
P values were calculated from a chi-square test or Fisher’s exact test for categorical variables, and the one-way 
analysis of variance or Kruskal-Wallis test for continuous variables. 
AVR=aortic valve replacement 
Other abbreviations are same as in supplementary table 1.  
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Supplementary Table 5. Clinical outcomes according to the malignancy status in the AVR cohort 
 
N of patients with event/N of patients at risk 
(Cumulative 3-year incidence [%])  
P value 
Adjusted risk 
HR 95% CI P value 
All-cause death 
No malignancy group 198/1067 (21.8%) 
0.001 
1 (reference)   
Past history group 31/114 (29.6%) 1.43 0.95-2.15 0.09 
Malignancy group 7/16 (56.7%) 1.79 0.77-4.15 0.17 
Malignancy 
related death 
No malignancy group 22/1067 (3.2%) 
0.01 
1 (reference)   
Past history group 2/114 (1.8%) 0.82 0.16-4.18 0.81 
Malignancy group 2/16 (14.4%) 10.93 1.87-64.00 0.008 
Aortic valve 
related death 
No malignancy group 61/1067 (6.0%) 
0.61 
1 (reference)   
Past history group 7/114 (6.3%) 1.29 0.58-2.86 0.53 
Malignancy group 0/16 (0.0%) 0.0 0.0 <0.001 
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Abbreviations are same as in supplementary table 2 and 3.
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Supplementary Table 6. The number of patients who underwent TAVI according to the 
malignancy status in the conservative management and initial AVR cohorts 
Initial treatment strategy 
N of patients who underwent TAVI/N of patients who 
underwent surgical AVR or TAVI 
P value 
Malignancy group Past history group 
No malignancy 
group  
Conservative management cohort 1/10 2/51 26/508 0.51 
Initial AVR cohort 0/15 3/113 8/1046 0.20 
TAVI=transcatheter aortic valve implantation 
Other abbreviations are same as in supplementary table 4.  
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Supplementary Table 7. Types of malignancy in the malignancy group (N=124) 
 
Number (N=124) 
Prostate cancer 24 
Lung cancer 19 
Gastric cancer 13 
Hepatic cancer 8 
Breast cancer 8 
Kidney and ureter cancer 7 
Malignant lymphoma 7 
Colon cancer 6 
Oral and pharyngeal cancer 5 
Bladder cancer 4 
Esophagus cancer 4 
Gall bladder and bile duct cancer 3 
Other cancers 16 
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